Amylyx Pharmaceuticals Inc [AMLX] stock is trading at $3.87, up 1.57%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AMLX shares have gain 3.75% over the last week, with a monthly amount glided 20.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] stock has seen the most recent analyst activity on November 18, 2024, when Robert W. Baird upgraded its rating to a Outperform and also boosted its price target to $11 from $3. Previously, BofA Securities upgraded its rating to Buy on October 23, 2024, and elevated its price target to $10. On March 18, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $4 on the stock. Robert W. Baird downgraded its rating to a Neutral and decreased its price target to $4 on March 11, 2024. Leerink Partners downgraded its rating to a Market Perform and reduced its price target to $4 on March 11, 2024. Goldman downgraded its rating to Neutral for this stock on March 08, 2024. In a note dated March 08, 2024, Evercore ISI downgraded an In-line rating on this stock.
Amylyx Pharmaceuticals Inc [AMLX] stock has fluctuated between $1.58 and $7.27 over the past year. Currently, Wall Street analysts expect the stock to reach $8.25 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $3.87 at the most recent close of the market. An investor can expect a potential return of 113.18% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] reported sales of 87.37M for the trailing twelve months, which represents a drop of -100.61%. Gross Profit Margin for this corporation currently stands at -0.43% with Operating Profit Margin at -3.34%, Pretax Profit Margin comes in at -3.46%, and Net Profit Margin reading is -3.45%. To continue investigating profitability, this company’s Return on Assets is posted at -1.56, Equity is -1.27 and Total Capital is -1.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.70 points at the first support level, and at 3.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.98, and for the 2nd resistance point, it is at 4.09.
Ratios To Look Out For
For context, Amylyx Pharmaceuticals Inc’s Current Ratio is 6.67. In addition, the Quick Ratio stands at 6.67 and the Cash Ratio stands at 2.72. Considering the valuation of this stock, the price to sales ratio is 3.92, the price to book ratio is 1.61.
Transactions by insiders
Recent insider trading involved Zeiher Bernhardt G, Director, that happened on Mar 20 ’25 when 10000.0 shares were purchased. Co-Chief Executive Officer, Klee Justin B. completed a deal on Mar 03 ’25 to sell 4595.0 shares. Meanwhile, Co-Chief Executive Officer Cohen Joshua B sold 4595.0 shares on Mar 03 ’25.
